Oxytocin, Stress, Craving, Opioid Use Disorder
A legfontosabb adatok
- Ki végzi
- Brown University
- Hol
- Providence (Egyesült Államok)A helyszín megnézése
- Azonosító
- Állapot
- Befejeződött
- Fázis
- 1. fázis
- Résztvevők
- 20 fő vett részt
- Kezdés
- 2020. jan. 6.
- Befejezés
- 2023. dec. 23.
- A vizsgálat típusa
- Beavatkozással járó, 2 csoportAz egyik csoport placebót (hatóanyag nélküli szert) kap, összehasonlításként.
- A vizsgált kezelések
- intranasal oxytocin, 40 IU, twice a day for 7 days
- A regiszteradat frissítve
- 2025. május 25.
Ki vehet részt
- Életkor
- 18 év – 70 év
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 12 feltétel megnézéseKevesebb
Ki vehet részt
- Male or female (50%), 18 to 70 (inclusive) years of age
- Currently meets DSM-5 criteria for OUD
- Currently on a stable dose of buprenorphine/naloxone or methadone for at least 3 months
- In good health as confirmed by medical history, physical examination and blood work (Liver function within 5x the Upper normal limits (AST/ALT) and renal function within 2x the Lower Normal Limit (bilirubin, creatine clearance)
- Willing to take medication and adhere to the study procedures;- Understand informed consent and questionnaires in English at an 8th grade level
- Clinical Opiate Withdrawal Scale (COWS) = 0 at study screening and prior laboratory sessions
Ki nem vehet részt
- Current use of medications that may interact with study medications
- Clinically significant electrolyte abnormalities, current rhinitis or use of vasoconstricting medications or prostaglandins
- Current substance disorder other than marijuana, nicotine and caffeine as assessed by self-report and urine toxicology screen at baseline
- History of hypersensitivity to study medications
- Women who are breastfeeding, test positive for pregnancy or are unwilling to use medically-approved birth control
- Suicide attempts in the last three months
Helyszínek itt: Egyesült Államok
- Brown UniversityProvidence, Egyesült Államok
A vizsgálatról
Mit akar kideríteni a vizsgálat
Although stress has long been linked to substance use, craving and relapse, there are no available medications that target stress-induced substance use disorder (SUD). In particular, with the rise in opioid use, there is still a crucial need for developing effective pharmacological treatments that target and integrate the complexity of this disease. The long term goal of this project is to identify the key neuroendocrine pathways that are responsible for stress-induced craving in individuals with opioid use disorder (OUD) in order to better understand how they can be effectively treated.
A vizsgálat 2 csoportja
- Oxytocin first, then placeboA vizsgált kezelés
Oxytocin was administered as 40 IU/0.12 mL nasal spray in each nostril once in the morning and once in the afternoon for 7 days. After a 2 day washout period, Placebo was administered as nasal spray in each nostril once in the morning and once in the afternoon for 7 days.
Kezelés: intranasal oxytocin, 40 IU, twice a day for 7 days
- Matching placebo, then oxytocinPlacebo, összehasonlításként
Placebo was administered as nasal spray in each nostril once in the morning and once in the afternoon for 7 days. After a 2 day washout period, oxytocin was administered as 40 IU/0.12 mL nasal spray in each nostril once in the morning and once in the afternoon for 7 days.
Kezelés: intranasal oxytocin, 40 IU, twice a day for 7 days
Adatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- Oxytocin to Reduce Stress-induced Craving in Individuals With Opioid Use Disorder
- A regiszteradat frissítve
- 2025. május 25.